Amanda Calvert

Dr. Amanda Calvert


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ACAmanda Calvert
Amanda Calvert
BBBrad J Biggerstaff
Brad J Biggerstaff
NTNathan A Tanner
Nathan A Tanner
MLMolly Lauterbach
Molly Lauterbach
RLRobert S Lanciotti
Robert S Lanciotti
Zika virus (ZIKV) has emerged as a major global public health concern in the last two years due to its link as a causative agent of human birth defects. Its rapid expansion into the Western Hemisphere as well as the ability to be transmitted from mother to fetus, through sexual transmission and possibly through blood transfusions has increased the need for a rapid and expansive public health response to this unprecedented epidemic. A non-invasive and rapid ZIKV diagnostic screening assay that can be performed in a clinical setting throughout pregnancy is vital for prenatal care of women living in areas of the world where exposure to the virus is possible. To meet this need we have developed a sensitive and specific reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) assay to detect ZIKV RNA in urine and serum with a simple visual detection. RT-LAMP results were shown to have a limit of detection 10-fold higher than qRT-PCR. As little as 1.2 RNA copies/μl was detected by RT-LAMP from a panel of 178 diagnostic specimens. The assay was shown to be highly specific for ZIKV RNA when tested with diagnostic specimens positive for dengue virus (DENV) and chikungunya virus (CHIKV). The assay described here illustrates the potential for a fast, reliable, sensitive and specific assay for the detection of ZIKV from urine or serum that can be performed in a clinical or field setting with minimal equipment and technological expertise.

1 December 2015 in Journal of Clinical Virology
Verified
Journal Article
Closed access
Amy LambertAmy Lambert
Amy Lambert
JVJason O. Velez
Jason O. Velez
ABAaron C. Brault
Aaron C. Brault
ACAmanda Calvert
Amanda Calvert
LBLesley Bell-Sakyi
Lesley Bell-Sakyi
OKOlga I. Kosoy
Olga I. Kosoy

20 October 2023 in Journal of Medical Entomology
Verified
Journal Article
Open access
PDF file
Holly HughesHolly Hughes
Holly Hughes
Joan L. KenneyJoan L. Kenney
Joan L. Kenney
ACAmanda Calvert
Amanda Calvert
Cache Valley virus (CVV) is a mosquito-borne virus in the genus Orthobunyavirus (Bunyavirales: Peribunyaviridae) that has been identified as a teratogen in ruminants causing fetal death and severe malformations during epizootics in the U.S. CVV has recently emerged as a viral pathogen causing severe disease in humans. Despite its emergence as a public health and agricultural concern, CVV has yet to be significantly studied by the scientific community. Limited information exists on CVV’s geographic distribution, ecological cycle, seroprevalence in humans and animals, and spectrum of disease, including its potential as a human teratogen. Here, we present what is known of CVV’s virology, ecology, and clinical disease in ruminants and humans. We discuss the current diagnostic techniques available and highlight gaps in our current knowledge and considerations for future research.

1 February 2006 in Journal of General Virology
Verified
Journal Article
Closed access
PDF file
ACAmanda Calvert
Amanda Calvert
CHClaire Y.-H. Huang
Claire Y.-H. Huang
RKRichard M. Kinney
Richard M. Kinney
JRJohn Roehrig
John Roehrig
Chimeric (D2/WN) viruses containing the pre-membrane (prM) and envelope (E) proteins ofWest Nile virus(WN virus) and the capsid (C) and non-structural proteins of dengue 2 (DEN2) virus were used to evaluate the protective immunity elicited by either the flaviviral E protein or non-structural proteins. AG129 interferon-deficient mice, previously shown to be protected against lethal DEN1 or DEN2 viral infection after vaccination with a wild-type or candidate vaccine strain of DEN1 or DEN2 virus, respectively, were immunized with chimeric D2/WN virus and then challenged with DEN2 virus. D2/WN chimeric viruses were non-pathogenic in AG129 mice. These viruses elicited little anti-DEN E antibody, high levels of anti-DEN NS1 antibody and no or very low levels of DEN2 virus-neutralizing antibodies. Only 15 % of D2/WN-immunized mice survived challenge with DEN2 virus. However, their mean survival time increased by 11–14 days over non-immunized controls. These results suggest that, whilst the non-structural proteins were able to enhance mean survival times of AG129 mice, this protection was not as effective as protection mediated by the E protein.

1 January 2014 in Vaccine
Verified
Journal Article
Closed access
ACAmanda Calvert
Amanda Calvert
KDKandice L. Dixon
Kandice L. Dixon
MDMark J. Delorey
Mark J. Delorey
CBCarol D. Blair
Carol D. Blair
JRJohn T. Roehrig
John T. Roehrig

1 June 2018 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
ACAmanda Calvert
Amanda Calvert
KBKaren L. Boroughs
Karen L. Boroughs
JLJaneen Laven
Janeen Laven
JSJanae L. Stovall
Janae L. Stovall
BLBetty E. Luy
Betty E. Luy
CHClaire Y.-H. Huang
Claire Y.-H. Huang
Zika virus (ZIKV) has emerged as a major global public health concern due to its link as a causative agent of human birth defects. Laboratory diagnosis of suspected ZIKV infections by serological testing of specimens collected a week or more after symptom onset primarily relies on detection of anti-ZIKV-specific IgM antibodies by enzyme-linked immunosorbent assay coupled with detection of ZIKV-specific neutralizing antibody by neutralization tests. A definitive diagnosis based on serological assays is possible during primary ZIKV infections; however, due to the cross-reactivity of antibodies elicited during flaviviral infections, a definitive diagnosis is not always possible, especially among individuals who have previously been exposed to closely related flaviviruses, such as dengue virus (DENV). Here, we investigated the neutralizing IgM antibody profiles of 33 diagnostic specimens collected from individuals with suspected primary and secondary flaviviral infections acquired when visiting areas experiencing active ZIKV transmission in 2015 and 2016. Specimens collected between 1 day and 3 months postexposure were tested for ZIKV and dengue virus type 1 (DENV1) and type 2 (DENV2) by the plaque reduction neutralization test (PRNT) before and after IgG depletion. We found that IgG depletion prior to neutralization testing had little effect in differentiating samples from individuals with secondary infections taken less than 3 weeks postexposure; however, IgG depletion significantly reduced the cross-reactive neutralizing antibody titers and increased the percentage of cases discernible by PRNT from 15.4% (95% confidence interval [CI], 4.3 to 42.2%) to 76.9% (95% CI, 49.7 to 91.8%) for samples collected between roughly 3 and 12 weeks postexposure. These results highlight the potential of IgG depletion to improve the specificity of PRNT for better confirmation and differential diagnosis of flavivirus infections.